{
    "ticker": "XBPEW",
    "name": "Xenon Pharmaceuticals Inc.",
    "description": "Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological disorders and other serious medical conditions. Founded in 1996 and headquartered in Burnaby, British Columbia, Canada, Xenon leverages its proprietary drug discovery platform and deep expertise in genetics to identify and develop treatments that address unmet medical needs. The company\u2019s lead product candidate, XEN496, is being investigated for the treatment of patients with KCNQ2 epileptic encephalopathy, a rare genetic condition that leads to severe seizures and developmental delays. In addition to XEN496, Xenon is advancing several other programs targeting various neurological disorders. The company is committed to precision medicine, aiming to tailor treatments based on individual genetic profiles. Xenon is dedicated to collaboration with academic and industry partners to enhance its research and development efforts and to accelerate the delivery of new therapies to patients. The company\u2019s mission is to improve the lives of individuals affected by neurological disorders through innovative science and compassionate care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Burnaby, British Columbia, Canada",
    "founded": "1996",
    "website": "https://www.xenon-pharma.com",
    "ceo": "Simon Pimstone",
    "social_media": {
        "twitter": "https://twitter.com/XenonPharma",
        "linkedin": "https://www.linkedin.com/company/xenon-pharmaceuticals/"
    },
    "investor_relations": "https://investors.xenon-pharma.com",
    "key_executives": [
        {
            "name": "Simon Pimstone",
            "position": "CEO"
        },
        {
            "name": "Catherine A. O\u2019Connor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Candidates",
            "products": [
                "XEN496",
                "XEN1101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Xenon Pharmaceuticals Inc. | Innovative Neurological Therapies",
        "meta_description": "Explore Xenon Pharmaceuticals Inc., a leader in developing therapies for neurological disorders. Learn about our innovative drug candidates and commitment to precision medicine.",
        "keywords": [
            "Xenon Pharmaceuticals",
            "Neurological Disorders",
            "Biotechnology",
            "Pharmaceuticals",
            "XEN496",
            "KCNQ2"
        ]
    },
    "faq": [
        {
            "question": "What is Xenon Pharmaceuticals known for?",
            "answer": "Xenon Pharmaceuticals is known for developing innovative therapies for neurological disorders and other serious medical conditions."
        },
        {
            "question": "Who is the CEO of Xenon Pharmaceuticals?",
            "answer": "Simon Pimstone is the CEO of Xenon Pharmaceuticals Inc."
        },
        {
            "question": "Where is Xenon Pharmaceuticals headquartered?",
            "answer": "Xenon Pharmaceuticals is headquartered in Burnaby, British Columbia, Canada."
        },
        {
            "question": "What are Xenon's main product candidates?",
            "answer": "Xenon's main product candidates include XEN496 and XEN1101."
        },
        {
            "question": "When was Xenon Pharmaceuticals founded?",
            "answer": "Xenon Pharmaceuticals was founded in 1996."
        }
    ],
    "competitors": [
        "SAGE",
        "NVCR",
        "IRWD",
        "ZGNX"
    ],
    "related_stocks": [
        "VRTX",
        "AMGN",
        "GILD",
        "BMY"
    ]
}